Back to CITADEL ADVISORS LLC CITADEL ADVISORS LLC

SXTCSXTC
3 quarters

Position history for CITADEL ADVISORS LLCCITADEL ADVISORS LLC's holdings in China SXT Pharmaceuticals, Inc.

No. Citadel Advisors exited its SXTC (China SXT Pharmaceuticals) position in Q1 2026. Its Q4 2025 13F listed 150,576 shares worth $240,922. Citadel Advisors first reported SXTC in Q3 2025 and held it in 2 quarterly 13F filings.

Final Value

$0

Final Shares

0

Total Value Change

-$77,527

Total Shares Change

-48,759

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q1
Latest
Exited
0
-100.0%
$00.0%$13,440.00
0
2025-Q4
Increased
150,576
+208.8%
$240,9220.0%$1,920,000.00
25
2025-Q3
New
48,759
-
$77,5270.0%$1,884,000.00
33

Other major holders of SXTC: Invesco Ltd., UBS Group AG, GEODE CAPITAL MANAGEMENT, LLC

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used